Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB123667 |
Synonyms | |
Therapy Description |
INCB123667 selectively inhibits CDK2, potentially leading to decreased growth of CCNE-overexpressing tumors (European Journal of Cancer 174 (2022): S79). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB123667 | INCB-123667|INCB 123667 | CDK2 Inhibitor 31 | INCB123667 selectively inhibits CDK2, potentially leading to decreased growth of CCNE-overexpressing tumors (European Journal of Cancer 174 (2022): S79). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | CHE | 1 |